Vironexis Biotherapeutics Launches with FDA Clearance of IND Application for First-Ever ...
Vironexis launches with $26M seed financing, focusing on AAV-delivered T-cell immunotherapy for safer, more effective cancer treatments. Their TransJoin™ platform supports over 10 product candidates, including VNX-101 for CD19+ acute lymphoblastic leukemia, set for Phase 1/2 trials in Q4 2024.
Related Clinical Trials
Highlighted Terms
Related News
Vironexis Biotherapeutics, leveraging its TransJoin™ AAV Gene Therapy Platform, aims to deliver safer, more effective, and long-lasting single-dose cancer treatments. The company has a pipeline of over 10 product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. Vironexis raised $26 million in seed financing and plans to advance its first two oncology programs into clinical trials in Q4 2024 and 2025.
Vironexis launches with $26M seed financing, focusing on AAV-delivered T-cell immunotherapy for safer, more effective cancer treatments. Their TransJoin™ platform supports over 10 product candidates, including VNX-101 for CD19+ acute lymphoblastic leukemia, set for Phase 1/2 trials in Q4 2024.
Vironexis Biotherapeutics' VNX-101, an AAV vector-based gene therapy for CD19+ acute lymphoblastic leukemia, received FDA IND clearance for a phase 1/2 trial. VNX-101 aims to express a bispecific T-cell engager in liver cells, targeting cancer cells and T-cells for killing. This marks the first AAV vector-based immunotherapy for cancer in clinical trials, leveraging the TransJoin platform. The therapy aims to improve safety, efficacy, and durability over existing treatments like CAR-T therapy and bispecific antibodies.
Vironexis Biotherapeutics, a biotech firm developing single-dose gene therapies for blood-based cancers, launched with $26 million in seed funding and 10+ candidate products. The company received FDA approval for its VNX-101 gene therapy candidate for CD19+ acute lymphoblastic leukemia and plans to start a Phase 1/2 trial in Q4 2024. Vironexis' gene therapies use proprietary TransJoin technology licensed from Nationwide Children's Hospital, aiming to turn the body into a 'drug manufacturing plant'.
The FDA has cleared an IND application for VNX-101, a gene therapy for CD19-positive ALL, marking the first AAV-delivered cancer immunotherapy trial. The phase 1/2 study (NCT06533579) is set to begin in Q4 2024, with primary endpoints focusing on safety and secondary endpoints on efficacy.
Vironexis Biotherapeutics launched with $26M seed financing, unveiling its TransJoin™ AAV Gene Therapy Platform for safer, more effective, and long-lasting cancer treatments. The company plans to advance its first two oncology programs into clinical trials in Q4 2024 and 2025, respectively.